Home › Funds › Franklin Biotechnology Discovery Fund
Fund family: FRANKLIN STRATEGIC SERIES · Filed by FRANKLIN STRATEGIC SERIES (CIK 872625) · SEC series S000006882
Share classes and tickers: FBDIX (C000018631), FBTDX (C000141458), FRBRX (C000128862), FTDZX (C000081539)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 634 with, 8 against, 0 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other FRANKLIN STRATEGIC SERIES funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 306 | 0 |
| Audit-related | 79 | 0 |
| Capital Structure | 69 | 0 |
| Compensation | 69 | 1 |
| Say-on-Pay | 67 | 0 |
| Corporate Governance | 55 | 4 |
| Other Social Issues | 3 | 2 |
| Shareholder Rights and Defenses | 2 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Gilead Sciences, Inc. | April 30, 2026 | $68M | 15 | 3 |
| Amgen Inc. | May 19, 2026 | $66M | 15 | 1 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $58M | 7 | 0 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $55M | 14 | 1 |
| argenx SE | May 6, 2026 | $47M | 12 | 0 |
| argenx SE | November 18, 2025 | $46M | 1 | 0 |
| Guardant Health, Inc. | June 17, 2026 | $36M | 5 | 0 |
| Revolution Medicines, Inc. | June 18, 2026 | $34M | 4 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | For | Against |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| June 30, 2026 | Inventiva SA | Authorize Capital Issuances for Use in Employee Stock Purchase Plans | For | Against |
651 ballot items at 80 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Franklin Biotechnology Discovery Fund (FBDIX) voted at 80 shareholder meetings of 77 companies, on 651 ballot items in all. Where management made a recommendation, the fund followed it on 98.8% of the items and voted against it 8 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 7 shareholder proposals.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.